Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

Crinetics (CRNX) Q1 2026 Earnings Transcript

This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.

This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations.

This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets.

Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology.

Crinetics (CRNX) Q4 2025 Earnings Call Transcript

As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused solely on the rare endocrine disorder Cushing’s syndrome, Corcept has evolved into a diversified clinical-stage powerhouse. While the company recently weathered a significant regulatory storm involving [...]

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

The company is preparing a rollout of its recently FDA-approved acromegaly treatment.

Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders.

Crinetics Q3 2025 earnings miss estimates as it transitions to a commercial-stage company following the U.S. launch of its new drug, PALSONIFY.

The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.

On Thursday, the U.S.

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.

Let's have a look at the gap up and gap down stocks in today's session.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.